A case study: neuroleptic malignant syndrome with risperidone and CYP2D6 gene variation

Area of Science:

• Pharmacogenomics
• Neuroscience
• Clinical Medicine

Background:

• Schizophrenia is a complex psychiatric disorder often managed with antipsychotic medications.
• Risperidone is a commonly prescribed second-generation antipsychotic.
• Neuroleptic Malignant Syndrome (NMS) is a rare but life-threatening adverse drug reaction to antipsychotics.

Observation:

• A patient diagnosed with schizophrenia experienced symptoms consistent with Neuroleptic Malignant Syndrome during treatment with risperidone.
• Genetic analysis revealed the patient possessed variants in the Cytochrome P450 family 2 subfamily D member 6 (CYP2D6) gene, leading to reduced enzyme function.

Findings:

• The patient's reduced CYP2D6 function likely impaired risperidone metabolism, potentially leading to increased drug levels and toxicity.
• This case suggests a pharmacogenetic link between CYP2D6 reduced function variants and the development of NMS in patients treated with risperidone.

Implications:

• Clinicians should consider CYP2D6 genotype in patients prescribed risperidone, especially those with a history of adverse drug reactions.
• Awareness of this pharmacogenetic interaction can aid in the early identification and prevention of NMS, improving patient safety.
• Further research into CYP2D6 genotype-guided antipsychotic therapy may optimize treatment outcomes for schizophrenia patients.